The sale of 860,123 shares at $45.36 reduces OrbiMed’s indirect holdings by 11.6% amid stock appreciation.
OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics (NASDAQ:ELVN) for $39.0 million, based on a weighted average price of $45.36. The transaction was disclosed in an SEC Form 4 filing on June 22, 2026, following a 130% rally in the stock over the past year.
Prior to the sale, OrbiMed held 7,415,225 shares indirectly. The sale represents 11.6% of its total indirect holdings, leaving 6,555,102 shares remaining. The stock closed at $45.96 on June 22 and rose to $50 by June 26, 2026, reflecting continued upward momentum post-transaction.
Enliven Therapeutics focuses on developing small-molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-mutant cancers.